Publication details
Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace)
| Title in English | Staging and Treatment Response Evaluation in Malignant Lymphomas – Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification) |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.14735/amko2016295 |
| Field | Oncology and hematology |
| Keywords | malignant lymphoma; computed tomography; positron emission tomography; staging; treatment response |
| Description | Background: Recent advances in the use of the imaging modalities, especially PET/CT, and their utilization for determining clinical stage (CS) and assessment treatment response (TR) in malignant lymphomas, along with development of prognostic tools and new treatment modalities, formed the basis for the revised criteria for evaluating CS and TR (published as the Lugano classifi cation, 2014). Materials and Methods: The authors summarize the new Lugano recommendations (published in 2014) and the changes from the criteria published in 2007. Moreover, discussion of the changes places emphasis on practical use. The practicality of the Lugano classifi cation, 2014 was the subject of consensus meeting at the annual meeting of the Cooperative Lymphoma Study Group (CLSG) in March 2015. This study reports the fi nal consensus. The CLSG recommends use of the Lugano classifi cation, 2014, but recommends some modifi cations. Conclusions: Standardization of the criteria used to determine CS and TR in malignant lymphomas has led to improvements in initial staging and assessment of TR. The criteria are helpful for unifying response assessment in clinical trials and simplify the work of regulatory agencies (e.g., the EMA and the Czech State Institute for Drug Control) when registering new drugs. It also allows evaluation of treatment outcomes outside clinical trials, for example within the CLSG prospective registry of patients with newly diagnosed lymphoma. |